

# Ehab Atallah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7142608/publications.pdf>

Version: 2024-02-01

72  
papers

1,331  
citations

394421

19  
h-index

395702

33  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	6.3	9
2	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
3	Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	24
4	Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2641-2649.	3.5	4
5	Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. <i>JCO Oncology Practice</i> , 2022, , OP2200237.	2.9	1
6	A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. <i>Journal of Cancer Prevention</i> , 2022, 27, 129-138.	2.0	4
7	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
8	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	7.1	51
9	Do histone deacetylase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 665-673.	4.1	2
10	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
11	Treatment-Free Remission: the New Goal in CML Therapy. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 433-439.	2.3	16
12	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	7.1	39
13	In Reply. <i>Oncologist</i> , 2020, 25, e744-e745.	3.7	0
14	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
15	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , 2020, 95, 106385.	0.8	26
16	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101-S102.	2.0	2
17	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 449-457.	5.2	37
18	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12

#	ARTICLE	IF	CITATIONS
19	Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?. <i>Haematologica</i> , 2020, 105, 2738-2745.	3.5	28
20	Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginaseâ€”A real world study. <i>Leukemia Research</i> , 2020, 94, 106368.	0.8	2
21	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	5.2	62
22	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 480-487.	0.4	11
23	Patientsâ€™ perspectives on the definition of cure in chronic myeloid leukemia. <i>Leukemia Research</i> , 2019, 80, 40-42.	0.8	4
24	Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258.	3.7	16
25	Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. <i>Leukemia and Lymphoma</i> , 2019, 60, 1171-1178.	1.3	25
26	Treatment-Free Remission in CML: the US Perspective. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 56-61.	2.3	13
27	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 1660-1672.	4.1	19
28	Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 79-81.	1.8	1
29	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	2.6	15
30	Incorporating newer agents in the treatment of acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 74, 113-120.	0.8	9
31	Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. <i>Case Reports in Hematology</i> , 2018, 2018, 1-6.	0.4	6
32	Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia Research</i> , 2018, 73, 21-23.	0.8	62
33	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.8	24
34	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
35	Chronic Myeloid Leukemiaâ€”the Promise of Tyrosine Kinase Inhibitor Discontinuation. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 415-423.	2.3	7
36	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017, 92, E563-E565.	4.1	4

#	ARTICLE	IF	CITATIONS
37	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 468-479.	3.8	10
38	Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 2016, 11, 80-85.	2.3	37
39	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 139-145.	0.4	60
40	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Blood, 2016, 128, 100-100.	1.4	18
41	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. Blood, 2016, 128, 2784-2784.	1.4	2
42	Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States. Blood, 2016, 128, 3992-3992.	1.4	1
43	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). Blood, 2016, 128, 5192-5192.	1.4	0
44	Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 214-221.e1.	0.4	63
45	Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e1-e5.	0.4	22
46	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. Blood, 2015, 126, 193-193.	1.4	11
47	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 453-453.	1.4	20
48	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. Blood, 2015, 126, 908-908.	1.4	17
49	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). Blood, 2015, 126, 4954-4954.	1.4	0
50	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	1.4	0
51	Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). Current Hematologic Malignancy Reports, 2014, 9, 57-65.	2.3	11
52	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 163-163.	1.4	12
53	Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes. Blood, 2014, 124, 1851-1851.	1.4	3
54	Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2014, 124, 947-947.	1.4	2

#	ARTICLE	IF	CITATIONS
55	A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. Blood, 2014, 124, LBA-5-LBA-5.	1.4	19
56	Relationship of Bone Marrow Blast (BMBl) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 3259-3259.	1.4	0
57	A Statistical Model for Predicting Neutropenic Fever. Blood, 2014, 124, 5258-5258.	1.4	0
58	D-Dimer Kinetics, Chemotherapy and Risk of Bleeding in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1490-1490.	1.4	0
59	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 2013, 7, 13.	2.0	46
60	Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia. Blood, 2013, 122, 5170-5170.	1.4	0
61	Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. Blood, 2012, 120, 1733-1733.	1.4	11
62	The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries. Blood, 2012, 120, 1983-1983.	1.4	3
63	Comparison of Outcomes After Related and Unrelated Hematopoietic Cell Transplantation in Adults with Myelodysplastic Syndromes: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2012, 120, 355-355.	1.4	1
64	The Effect of Hyperglycemia On the Outcome of Patients with Acute Myelogenous Leukemia. Blood, 2012, 120, 4323-4323.	1.4	0
65	Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. American Journal of Hematology, 2010, 85, 579-583.	4.1	5
66	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy, 2009, 9, 663-670.	2.4	28
67	Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 2081-2081.	1.4	3
68	Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.. Blood, 2009, 114, 2089-2089.	1.4	12
69	Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.. Blood, 2009, 114, 4157-4157.	1.4	0
70	Treatment Strategies in Myelodysplastic Syndromes. Cancer Investigation, 2008, 26, 208-216.	1.3	13
71	Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Blood, 2008, 112, 3651-3651.	1.4	6
72	Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood, 2007, 110, 1233-1237.	1.4	233